Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD80
  • Lymphoma, Follicular

abstract

  • The favorable safety profile of galiximab and evidence of single-agent biologic activity and dose-dependent pharmacokinetics support further evaluation of galiximab as a treatment for follicular lymphoma, possibly in combination with other lymphoma therapies.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.09.018

PubMed ID

  • 15994148

Additional Document Info

start page

  • 4390

end page

  • 8

volume

  • 23

number

  • 19